Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials
Authors: Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Alexa B Kimball